Achilles Therapeutics plc (NASDAQ:ACHL – Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 122,300 shares, a growth of 35.4% from the December 15th total of 90,300 shares. Based on an average daily volume of 169,400 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.3% of the shares of the stock are sold short.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Achilles Therapeutics stock. XTX Topco Ltd increased its stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL – Free Report) by 239.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 51,660 shares of the company’s stock after purchasing an additional 36,441 shares during the quarter. XTX Topco Ltd owned approximately 0.13% of Achilles Therapeutics worth $42,000 at the end of the most recent reporting period. Institutional investors own 56.38% of the company’s stock.
Achilles Therapeutics Stock Down 0.9 %
ACHL stock opened at $1.15 on Friday. Achilles Therapeutics has a 12 month low of $0.63 and a 12 month high of $1.76. The firm has a market cap of $47.27 million, a P/E ratio of -0.70 and a beta of 1.32. The company’s 50-day moving average price is $1.08 and its two-hundred day moving average price is $0.94.
About Achilles Therapeutics
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.
Featured Articles
- Five stocks we like better than Achilles Therapeutics
- What is the S&P 500 and How It is Distinct from Other Indexes
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Canada Bond Market Holiday: How to Invest and Trade
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Achilles Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achilles Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.